Early research (Phase 1)Study completedNCT02015416
What this trial is testing
Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Who this might be right for
MelanomaOvarian CancerSarcoma+2 more
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 13